Gilead Sciences has acquired Phenex Pharmaceuticals’ development programme for the treatment of serious liver diseases. The US biopharma firm will …

GE Healthcare and Takeda Pharmaceutical have joined forces to develop treatments which target liver conditions including non-alcoholic fatty liver disease …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

